IRMD logo

IRadimed (IRMD) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

16 July 2014

Indexes:

Not included

Description:

IRadimed is a medical technology company that specializes in developing innovative MRI-compatible devices. Their products, including infusion pumps and monitoring systems, enhance patient safety and comfort during MRI procedures, making them essential for hospitals and healthcare providers.

Key Details

Price

$55.52

TTM Dividend Yield

0.81%(-41.30% YoY)

PE Ratio

38.03(+13.08% YoY)

Beta

0.97

Events Calendar

Earnings

Next earnings date:

Feb 07, 2025

Recent quarterly earnings:

Oct 31, 2024

Recent annual earnings:

Feb 08, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Nov 15, 2024
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

02 Aug '24 Roth MKM
Buy
02 Aug '21 Roth Capital
Buy
31 July '17 Roth Capital
Buy
05 Oct '16 Roth Capital
Neutral
04 Apr '16 Roth Capital
Buy
16 June '15 Roth Capital
Buy
11 Aug '14 Roth Capital

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Here's Why Momentum in iRadimed (IRMD) Should Keep going
Here's Why Momentum in iRadimed (IRMD) Should Keep going
Here's Why Momentum in iRadimed (IRMD) Should Keep going
IRMD
zacks.com13 December 2024

iRadimed (IRMD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

IRADIMED CORPORATION on Forbes' List of America's Most Successful Small-Cap Companies for 2025
IRADIMED CORPORATION on Forbes' List of America's Most Successful Small-Cap Companies for 2025
IRADIMED CORPORATION on Forbes' List of America's Most Successful Small-Cap Companies for 2025
IRMD
globenewswire.com10 December 2024

WINTER SPRINGS, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), today announced it has been ranked 24th on Forbes' list of America's Most Successful Small-Cap Companies 2025. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable
iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable
iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable
IRMD
zacks.com07 November 2024

iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

IRADIMED CORPORATION (IRMD) Q3 2024 Earnings Call Transcript
IRADIMED CORPORATION (IRMD) Q3 2024 Earnings Call Transcript
IRADIMED CORPORATION (IRMD) Q3 2024 Earnings Call Transcript
IRMD
seekingalpha.com31 October 2024

IRADIMED CORPORATION. (NASDAQ:IRMD ) Q3 2024 Earnings Conference Call October 31, 2024 11:00 AM ET Company Participants Roger Susi - President and Chief Executive Officer Jack Glenn - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jason Wittes - ROTH Capital Partners Operator Welcome to the IRadimed Corporation Third Quarter of 2024 Financial Results Conference Call.

IRadimed (IRMD) Beats Q3 Earnings and Revenue Estimates
IRadimed (IRMD) Beats Q3 Earnings and Revenue Estimates
IRadimed (IRMD) Beats Q3 Earnings and Revenue Estimates
IRMD
zacks.com31 October 2024

IRadimed (IRMD) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.43 per share a year ago.

IRADIMED CORPORATION to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
IRADIMED CORPORATION to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
IRADIMED CORPORATION to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
IRMD
globenewswire.com03 October 2024

WINTER SPRINGS, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it will participate in the 3rd Annual ROTH Healthcare Opportunities Conference.

IRADIMED CORPORATION To Participate in the Lake St. Annual Best Ideas Growth “Big 8” Investor Conference
IRADIMED CORPORATION To Participate in the Lake St. Annual Best Ideas Growth “Big 8” Investor Conference
IRADIMED CORPORATION To Participate in the Lake St. Annual Best Ideas Growth “Big 8” Investor Conference
IRMD
globenewswire.com10 September 2024

WINTER SPRINGS, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that the Company will be participating in the Lake Street 8 th  Annual Best Ideas Growth "Big 8" Conference.

IRADIMED CORPORATION (IRMD) Q2 2024 Earnings Call Transcript
IRADIMED CORPORATION (IRMD) Q2 2024 Earnings Call Transcript
IRADIMED CORPORATION (IRMD) Q2 2024 Earnings Call Transcript
IRMD
seekingalpha.com03 August 2024

IRADIMED CORPORATION (NASDAQ:IRMD ) Q2 2024 Results Conference Call August 1, 2024 12:00 PM ET Company Participants Roger Susi - President and Chief Executive Officer Matt Garner - Controller Conference Call Participants Frank Takkinen - Lake Street Capital Jason Wittes - ROTH Capital Partners Operator Welcome to the IRadimed Corporation Second Quarter of 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, August 1, 2024, and contains time-sensitive accurate information only today.

IRADIMED CORPORATION Announces Second Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
IRADIMED CORPORATION Announces Second Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
IRADIMED CORPORATION Announces Second Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
IRMD
globenewswire.com01 August 2024

WINTER SPRINGS, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three and six months ended June 30, 2024. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

IRADIMED CORPORATION to Hold 2024 Second Quarter Financial Results Conference Call on August 1st
IRADIMED CORPORATION to Hold 2024 Second Quarter Financial Results Conference Call on August 1st
IRADIMED CORPORATION to Hold 2024 Second Quarter Financial Results Conference Call on August 1st
IRMD
globenewswire.com25 July 2024

Winter Springs, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 second quarter financial results before the market opens on Thursday, August 1, 2024. Iradimed management will host a conference call the same day beginning at 12:00 p.m. Eastern Time to discuss those results and to answer questions.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the primary business of IRadimed?
  • What is the ticker symbol for IRadimed?
  • Does IRadimed pay dividends?
  • What sector is IRadimed in?
  • What industry is IRadimed in?
  • What country is IRadimed based in?
  • When did IRadimed go public?
  • Is IRadimed in the S&P 500?
  • Is IRadimed in the NASDAQ 100?
  • Is IRadimed in the Dow Jones?
  • When was IRadimed's last earnings report?
  • When does IRadimed report earnings?
  • Should I buy IRadimed stock now?

What is the primary business of IRadimed?

IRadimed is a medical technology company that specializes in developing innovative MRI-compatible devices. Their products, including infusion pumps and monitoring systems, enhance patient safety and comfort during MRI procedures, making them essential for hospitals and healthcare providers.

What is the ticker symbol for IRadimed?

The ticker symbol for IRadimed is NASDAQ:IRMD

Does IRadimed pay dividends?

Yes, IRadimed pays dividends. The last payment was $0.15, with an ex-dividend date on 15 November 2024

What sector is IRadimed in?

IRadimed is in the Healthcare sector

What industry is IRadimed in?

IRadimed is in the Medical Devices industry

What country is IRadimed based in?

IRadimed is headquartered in United States

When did IRadimed go public?

IRadimed's initial public offering (IPO) was on 16 July 2014

Is IRadimed in the S&P 500?

No, IRadimed is not included in the S&P 500 index

Is IRadimed in the NASDAQ 100?

No, IRadimed is not included in the NASDAQ 100 index

Is IRadimed in the Dow Jones?

No, IRadimed is not included in the Dow Jones index

When was IRadimed's last earnings report?

IRadimed's most recent earnings report was on 31 October 2024

When does IRadimed report earnings?

The next expected earnings date for IRadimed is 7 February 2025

Should I buy IRadimed stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions